Logo

Abbott's Epic Plus Tissue Valves Receives the US FDA's Approval for the Treatment of Mitral or Aortic Valve Replacement

Share this

Abbott's Epic Plus Tissue Valves Receives the US FDA's Approval for the Treatment of Mitral or Aortic Valve Replacement

Shots:

  • The US FDA has approved Abbott’s Epic Plus & Epic Plus Supra Stented Tissue valves to treat patients with aortic or MV disease who undergoes valve replacement surgery. The devices build off Abbott's Epic surgical valve platform
  • Abbott's Epic valve including radiopaque markers helps to improve implantation & allows compatibility for future transcatheter valve procedures. The new valves are designed to deliver long-term performance & durability due to Abbott's anti calcification technology
  • The Epic Plus Mitral holder helps to certify a precise insertion of the valve. The device can be implanted in the aortic or mitral valve position & in patients with complicated anatomies

Click here  | Ref: Abbott | Image: Abbott

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions